Trinity Biotech (TRIB)
(Delayed Data from NSDQ)
$1.65 USD
-0.01 (-0.60%)
Updated May 9, 2024 03:59 PM ET
After-Market: $1.65 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Trinity Biotech PLC [TRIB]
Reports for Purchase
Showing records 81 - 100 ( 101 total )
Company: Trinity Biotech PLC
Industry: Medical - Products
Healthcare - 2Q 2012: Quarterly Medical Technology Trading & Acquisition Valuation Update
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: Trinity Biotech PLC
Industry: Medical - Products
Healthcare: Med Tech: The Vote Is In - ACA Upheld; Device Tax a Headwind into 2013
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: Trinity Biotech PLC
Industry: Medical - Products
Med Tech Earnings Wrap-Up: What Looks Good Out of 1Q12
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: Trinity Biotech PLC
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Trinity Biotech PLC
Industry: Medical - Products
Raising Target Price; New Product Revs Pick Up in 2H12; Maintain Buy
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: Trinity Biotech PLC
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Trinity Biotech PLC
Industry: Medical - Products
Company: Trinity Biotech PLC
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Trinity Biotech PLC
Industry: Medical - Products
Company: Trinity Biotech PLC
Industry: Medical - Products
Still a Value Play - First Time Guidance; Need Growth from New Products
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: Trinity Biotech PLC
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Trinity Biotech PLC
Industry: Medical - Products
4Q11 Preview: EPS Again Has Upside; Updates on Premier, Fiomi Acquisition
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M